Synopsys, Inc. (SNPS) is currently at $646.13, up $53.50 or 9.03% --Would be new all-time high (Based on available data back to Feb. 26, 1992) --Would be the first new record closing high since July 5 ...

Cadence Design Systems (CDNS) tops Q2 expectations, lifts 2025 outlook amid AI-driven demand. Analysts boost price targets; ...

Dental caries remains a significant global public health burden, affecting billions worldwide despite preventive measures. While behavioral and ...

There's plenty of reason to be optimistic about Synopsys' future; however, whether it could realistically make you a ...

Researchers evaluated the relative importance of phenotypic and genetic factors in predicting risk for head and neck cancer.

A nascent hypothesis regarding pulmonary arterial hypertension (PAH) is that there is a link between thyroid dysfunction and PAH risk; much remains to be investigated to prove causality.

Shares of Synopsys Inc. SNPS slid 1.33% to $601.55 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to 6,388.64 and ...

Synopsys (SNPS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Valued at more than $95.4 billion by market cap, Sunnyvale, California-based Synopsys, Inc. (SNPS) operates as a vendor of ...

This study reveals how machine learning models uncover new genetic variants linked to Alzheimer’s, advancing predictive ...

Buying $1000 In SNPS: If an investor had bought $1000 of SNPS stock 15 years ago, it would be worth $26,611.09 today based on a price of $587.59 for SNPS at the time of writing.

A team of researchers has developed the first high-resolution genetic map and a versatile SNP chip for Panax ginseng, a ...